- Home
- SLN vs AOMR Comparison
SLN vs AOMR Comparison
Compare SLN & AOMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLN
- AOMR
- Stock Information
- Founded
- SLN 1994
- AOMR 2018
- Country
- SLN United Kingdom
- AOMR United States
- Employees
- SLN N/A
- AOMR N/A
- Industry
- SLN Biotechnology: Pharmaceutical Preparations
- AOMR Real Estate Investment Trusts
- Sector
- SLN Health Care
- AOMR Real Estate
- Exchange
- SLN Nasdaq
- AOMR Nasdaq
- Market Cap
- SLN 268.8M
- AOMR 224.3M
- IPO Year
- SLN N/A
- AOMR 2021
- Fundamental
- Price
- SLN $6.59
- AOMR $9.25
- Analyst Decision
- SLN Buy
- AOMR Strong Buy
- Analyst Count
- SLN 6
- AOMR 6
- Target Price
- SLN $39.67
- AOMR $11.25
- AVG Volume (30 Days)
- SLN 115.5K
- AOMR 96.4K
- Earning Date
- SLN 11-13-2025
- AOMR 11-05-2025
- Dividend Yield
- SLN N/A
- AOMR 13.85%
- EPS Growth
- SLN N/A
- AOMR N/A
- EPS
- SLN N/A
- AOMR 1.56
- Revenue
- SLN $27,169,000.00
- AOMR $57,661,000.00
- Revenue This Year
- SLN N/A
- AOMR N/A
- Revenue Next Year
- SLN N/A
- AOMR $12.91
- P/E Ratio
- SLN N/A
- AOMR $5.91
- Revenue Growth
- SLN 22.28
- AOMR N/A
- 52 Week Low
- SLN $1.97
- AOMR $7.36
- 52 Week High
- SLN $19.36
- AOMR $10.88
- Technical
- Relative Strength Index (RSI)
- SLN 69.56
- AOMR 42.52
- Support Level
- SLN $5.00
- AOMR $8.98
- Resistance Level
- SLN $5.83
- AOMR $9.42
- Average True Range (ATR)
- SLN 0.41
- AOMR 0.15
- MACD
- SLN 0.16
- AOMR -0.01
- Stochastic Oscillator
- SLN 93.42
- AOMR 44.00
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
About AOMR Angel Oak Mortgage REIT Inc.
Angel Oak Mortgage REIT Inc is a real estate finance company focused on acquiring and investing in the first lien non-QM loans and other mortgage-related assets in the U.S. mortgage market. Its objective is to generate attractive risk-adjusted returns for its stockholders, through cash distributions and capital appreciation across interest rates and credit cycles.